marked.bio

Company

Jemincare

3 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

ifebemtinib 1

Trials

3 of 3 trials shown

  1. Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

    Not yet recruiting Phase 3 Jemincare Started 2025Primary completion 2027-12 NCT07242274

    JMKX001899docetaxel

    Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

    KRAS G12CNSCLC (Non-small Cell Lung Cancer)

  2. A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

    Recruiting Phase 1 Jemincare Started 2025Primary completion 2026-02 NCT06946927

    JMKX001899ifebemtinibpemetrexedcarboplatin

    Known KRAS G12C mutation, and negative results for other driver genes with approved targeted therapies.

    KRAS G12CNSCLC (Advanced Non-small Cell Lung Cancer)

  3. A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors

    Recruiting Phase 1 Jemincare Started 2025Primary completion 2027-12 NCT07208136

    JMKX005425

    Have a microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR), histologically or cytologically documente…

    MSI-H / dMMRAdvanced Solid Tumors